American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Spleen Size Prior to Fedratinib Treatment May Impact Spleen Responses and Symptom Reduction in Myelofibrosis Patients

ASH 2021 - Myelofibrosis

Clinical trials have demonstrated JAK2 inhibition with fedratinib effectively reduces spleen volume and improves symptoms in patients with myelofibrosis. It has yet to be determined whether spleen size before fedratinib therapy influences these effects. Read More ›

Pacritinib Demonstrates Superior Efficacy to Low-Dose Ruxolitinib in Myelofibrosis Patients with Thrombocytopenia

ASH 2021 - Myelofibrosis

Low-dose ruxolitinib is an approved therapy for patients with myelofibrosis who have thrombocytopenia, but efficacy may be limited. Evidence from PERSIST-2 indicate pacritinib at full dose may provide additional clinical benefit with a similar safety profile compared with ruxolitinib. Read More ›

Enhanced Benefit of Extended Treatment with Pacritinib in Patients with Advanced Myelofibrosis and Cytopenias

ASH 2021 - Myelofibrosis

Pacritinib is currently under investigation in multiple trials and demonstrated efficacy and safety in patients with advanced myelofibrosis during the study period. Patients who continue pacritinib on a compassionate-use basis show further improvement in clinical outcomes. Read More ›

Navtemadlin Improves Clinical Outcomes in Patients with Relapsed/Refractory Myelofibrosis by Disease Modification

ASH 2021 - Myelofibrosis

Patients with myelofibrosis who are refractory to JAK inhibitors often lack effective treatment options that not only manage symptoms but can also reduce disease progression. Navtemadlin may improve disease burden in these patients through disease modification. Read More ›

Preliminary Evidence for Safe Administration of Ruxolitinib During and After Hematopoietic Stem-Cell Transplantation in Patients with Myelofibrosis

ASH 2021 - Myelofibrosis

Myelofibrosis patients typically prepare for allo-SCT by suspending ruxolitinib therapy, which subsequently results in worsening disease manifestations. Continuation of ruxolitinib therapy in an off-label approach offers a safer option according to interim phase 2 data. Read More ›

Pelabresib Provides Clinical Benefit in Patients with Myelofibrosis Ineligible or Intolerant to Ruxolitinib Therapy

ASH 2021 - Myelofibrosis

Myelofibrosis patients refractory to JAK inhibitor therapy typically have poor prognosis. Pelabresib demonstrates improvement in clinical outcomes while maintaining an acceptable safety profile in this patient subset. Read More ›

Early Data Demonstrate Selinexor as Safe and Effective Monotherapy in Patients with Myelofibrosis

ASH 2021 - Myelofibrosis

Patients with myelofibrosis who are refractory to JAK inhibitors often lack safe and effective treatment options. Selinexor may slow disease progression by reducing growth of malignant myelofibrosis cells. Read More ›

Fedratinib Demonstrates Efficacy in Patients with Myelofibrosis with Prior Ruxolitinib Therapy

ASH 2021 - Myelofibrosis

Ruxolitinib is an approved therapy for myelofibrosis but some patients experience serious side effects. Fedratinib is an effective therapeutic option for these patients without development of severe adverse events. Read More ›

Sotatercept Improves Anemia in Patients with Myelofibrosis

ASH 2021 - Myelofibrosis

Anemia is a common side effect in many patients with myelofibrosis on ruxolitinib therapy. Phase 2 clinical trial data demonstrate mitigation of anemia indices in this patient population by sotatercept. Read More ›

Two Different Doses of Ixazomib Assessed in Patients with Relapsed MM Not Refractory to Bortezomib

A randomized phase 2 study evaluated the safety and antimyeloma activity of 2 different doses of ixazomib (4 mg or 5.5 mg weekly for 3 weeks with a week off) plus dexamethasone (40 mg weekly) in patients with relapsed multiple myeloma (MM) but who were not refractory to bortezomib; results of this study were reported at the meeting. Read More ›

American Society of Hematology (ASH)

Page 3 of 44